Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19276860 | COMPOSITIONS AND METHODS RELATED TO GPRC5D BINDING AGENTS AND VARIANTS THEREOF | July 2025 | October 2025 | Allow | 3 | 0 | 0 | No | No |
| 18953634 | METHODS AND COMPOSITIONS FOR DOSING OF ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR T CELLS | November 2024 | November 2025 | Allow | 12 | 2 | 0 | No | No |
| 18409191 | IMMUNOCOMPETENT CELL THAT EXPRESSES A CELL SURFACE MOLECULE SPECIFICALLY RECOGNIZING HUMAN MESOTHELIN, IL-7 AND CCL19 | January 2024 | December 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18570578 | ANTI-CD3 CONSTRUCTS AND USES THEREOF | December 2023 | October 2024 | Allow | 10 | 1 | 0 | Yes | No |
| 18484244 | METHODS AND COMPOSITIONS FOR DOSING OF ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR T CELLS | October 2023 | May 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18374956 | ENGINEERED IMMUNE CELLS TARGETING BCMA AND THEIR USES THEREOF | September 2023 | September 2025 | Allow | 24 | 1 | 0 | Yes | No |
| 18363417 | CHIMERIC ANTIGEN RECEPTORS TARGETING ABNORMAL GLYCOBIOLOGY | August 2023 | May 2025 | Allow | 22 | 1 | 0 | No | No |
| 18331556 | IMPROVED DUAL SPECIFICITY POLYPEPTIDE MOLECULE | June 2023 | January 2026 | Abandon | 31 | 2 | 0 | No | No |
| 18331859 | ANTI-CD20 ANTIBODY AND USES THEREOF | June 2023 | November 2025 | Allow | 29 | 2 | 0 | No | No |
| 18331855 | ANTI-CD20 ANTIBODY AND USES THEREOF | June 2023 | September 2025 | Allow | 27 | 2 | 0 | No | No |
| 18331862 | ANTI-CD20 ANTIBODY AND USES THEREOF | June 2023 | January 2026 | Allow | 32 | 2 | 0 | No | No |
| 18206269 | CD33 EXON 2 DEFICIENT DONOR STEM CELLS FOR USE WITH CD33 TARGETING AGENTS | June 2023 | August 2025 | Abandon | 27 | 1 | 1 | No | No |
| 18321820 | IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | May 2023 | April 2025 | Allow | 23 | 1 | 0 | No | No |
| 18322450 | CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE | May 2023 | October 2025 | Abandon | 28 | 1 | 0 | No | No |
| 18314727 | IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | May 2023 | April 2025 | Allow | 23 | 1 | 0 | No | No |
| 18309303 | LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS | April 2023 | August 2025 | Allow | 28 | 1 | 0 | No | No |
| 18304956 | TREATMENT OF CANCER USING CHIMERIC CD3 RECEPTOR PROTEINS | April 2023 | July 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18297562 | ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR B-CELL MATURATION ANTIGEN | April 2023 | July 2025 | Abandon | 27 | 0 | 1 | No | No |
| 18192715 | B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | March 2023 | March 2025 | Allow | 24 | 1 | 0 | No | No |
| 18189443 | B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | March 2023 | February 2025 | Allow | 23 | 1 | 0 | No | No |
| 18189448 | B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | March 2023 | February 2025 | Allow | 23 | 1 | 0 | No | No |
| 18120020 | EXPRESSION AND SECRETION SYSTEM | March 2023 | May 2025 | Abandon | 26 | 1 | 0 | No | No |
| 18042763 | MODIFIED CAS9 SYSTEM HAVING A DOMINANT NEGATIVE EFFECTOR ON NON-HOMOLOGOUS END-JOINING FUSED THERETO AND ITS USE FOR IMPROVED GENE EDITING | February 2023 | September 2025 | Allow | 30 | 3 | 1 | Yes | No |
| 18170154 | B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | February 2023 | August 2024 | Allow | 17 | 0 | 0 | No | No |
| 18158754 | A CELL LEXPRESSING TWO CHIMERIC ANTIGEN RECEPTORS (CARS) AT THE CELL SURFACE | January 2023 | April 2025 | Allow | 27 | 2 | 0 | Yes | No |
| 18147981 | UTILIZATION OF CD39 AND CD103 FOR IDENTIFICATION OF HUMAN TUMOR REACTIVE T CELLS FOR TREATMENT OF CANCER | December 2022 | April 2025 | Allow | 27 | 1 | 1 | Yes | No |
| 18064880 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | December 2022 | October 2025 | Abandon | 34 | 1 | 1 | No | No |
| 18061805 | METHODS FOR CANCER TREATMENT | December 2022 | April 2025 | Abandon | 29 | 1 | 0 | No | No |
| 18059746 | COMPOSITIONS, ASSAYS, AND METHODS FOR DIRECT MODULATION OF FATTY ACID METABOLISM | November 2022 | March 2025 | Allow | 27 | 1 | 1 | Yes | No |
| 18056572 | CD8-SPECIFIC ANTIBODY CONSTRUCTS AND COMPOSITIONS THEREOF | November 2022 | March 2025 | Allow | 28 | 1 | 1 | Yes | No |
| 18055188 | BCMA BINDING MOLECULES AND METHODS OF USE THEREOF | November 2022 | April 2025 | Abandon | 29 | 1 | 0 | No | No |
| 18049470 | ANTI-CD276 POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS | October 2022 | April 2025 | Abandon | 30 | 1 | 0 | No | No |
| 17907648 | CHIMERIC ANTIGEN RECEPTORS TARGETING CD33 | September 2022 | November 2025 | Allow | 60 | 1 | 0 | Yes | No |
| 17954070 | METHODS OF CONDITIONING PATIENTS FOR T CELL THERAPY | September 2022 | May 2025 | Allow | 31 | 2 | 1 | Yes | No |
| 17953114 | Anti-MUC16 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Molecules that Bind MUC16 and CD3, and Uses Thereof | September 2022 | November 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17904941 | ENGINEERED T CELL RECEPTORS AND METHODS OF USE | August 2022 | March 2026 | Allow | 42 | 1 | 1 | No | No |
| 17801458 | NOVEL METHODS FOR CREATING ALPHA-N-METHYLATED POLYPEPTIDES | August 2022 | March 2026 | Abandon | 43 | 1 | 0 | No | No |
| 17817308 | CONSTRUCTS SPECIFICALLY RECOGNIZING GLYPICAN 3 AND USES THEREOF | August 2022 | July 2025 | Allow | 36 | 2 | 0 | Yes | No |
| 17816986 | USE OF HUMAN EPIDIDYMIS PROTEIN 4 (HE4) FOR ASSESSING RESPONSIVENESS OF MUC 16-POSITIVE CANCER TREATMENT | August 2022 | January 2025 | Abandon | 30 | 0 | 1 | No | No |
| 17791415 | METHOD AND ANTIBODY FOR DETECTION OF HBCAG | July 2022 | January 2026 | Allow | 43 | 2 | 0 | Yes | No |
| 17853576 | CIRCULAR RNA ENCODING CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA | June 2022 | October 2023 | Allow | 16 | 3 | 1 | Yes | No |
| 17849561 | RECEPTOR-BASED ANTAGONISTS OF THE PROGRAMMED CELL DEATH 1 (PD-1) PATHWAY | June 2022 | October 2025 | Abandon | 40 | 2 | 1 | No | No |
| 17788723 | CHIMERIC ANTIGEN RECEPTORS THAT BIND TO PROSTATE SPECIFIC MEMBRANE ANTIGEN | June 2022 | January 2025 | Allow | 30 | 4 | 0 | Yes | No |
| 17847909 | MULTIPLE ANTIGEN BINDING MOLECULAR FUSION, PHARMACEUTICAL COMPOSITION, METHOD FOR IDENTIFYING LINEAR EPITOPE, AND METHOD FOR PREPARING MULTIPLE ANTIGEN BINDING MOLECULAR FUSION | June 2022 | April 2025 | Allow | 34 | 1 | 1 | No | No |
| 17832290 | IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | June 2022 | September 2024 | Allow | 27 | 1 | 0 | No | No |
| 17829183 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORS | May 2022 | August 2025 | Abandon | 38 | 1 | 1 | No | No |
| 17826557 | IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | May 2022 | September 2024 | Allow | 27 | 1 | 0 | No | No |
| 17826583 | IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS | May 2022 | January 2025 | Abandon | 32 | 1 | 0 | No | No |
| 17745067 | CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN | May 2022 | September 2024 | Allow | 28 | 1 | 0 | No | No |
| 17734512 | DNA VACCINE AGAINST AMYLOID-BETA AND TAU | May 2022 | December 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17732232 | PEPTIDE-HINGE-FREE FLEXIBLE ANTIBODY-LIKE MOLECULE | April 2022 | March 2025 | Allow | 35 | 2 | 0 | Yes | No |
| 17725240 | COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATING CANCER | April 2022 | September 2025 | Allow | 41 | 2 | 0 | No | No |
| 17720766 | Anti-FOLR1 Immunoconjugate Dosing Regimens | April 2022 | September 2025 | Abandon | 41 | 2 | 0 | No | Yes |
| 17718975 | Fusion Comprising A Cell Penetrating Peptide, A Multi Epitope And A TLR Peptide Agonist For Treatment Of Cancer | April 2022 | August 2024 | Allow | 29 | 1 | 0 | No | No |
| 17718513 | BENZOQUINONE DERIVATIVES FOR THE TREATMENT OF BLADDER CANCER | April 2022 | February 2026 | Abandon | 47 | 1 | 1 | No | No |
| 17716547 | COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR TREATMENT OF CANCER | April 2022 | December 2024 | Abandon | 33 | 1 | 0 | No | No |
| 17716026 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST SMALL CELL LUNG CANCER AND OTHER CANCERS | April 2022 | August 2024 | Allow | 28 | 1 | 0 | No | No |
| 17655519 | FGFR/PD-1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER | March 2022 | October 2025 | Allow | 43 | 3 | 0 | Yes | No |
| 17692838 | NEUTRALIZING ANTIBODIES TO SARS-COV-2 AND ITS VARIANTS | March 2022 | May 2025 | Abandon | 38 | 3 | 1 | Yes | No |
| 17689698 | FLT3-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND METHODS USING SAME | March 2022 | September 2024 | Allow | 30 | 1 | 0 | Yes | No |
| 17681139 | COMPOSITIONS TARGETING THE INTERACTION DOMAIN BETWEEN P27KIP1 AND BRK AND METHODS OF USE THEREOF TO INHIBIT P27 Y PHOSPHORYLATION AND CDK4 ACTIVITY | February 2022 | August 2024 | Allow | 29 | 1 | 1 | Yes | No |
| 17665117 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CLL AND OTHER CANCERS | February 2022 | November 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17586984 | ANTIBODIES BINDING TO GPRC5D | January 2022 | November 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17649200 | METHODS OF TREATING CANCERS WITH CT45 TARGETED THERAPIES | January 2022 | August 2024 | Allow | 30 | 1 | 1 | Yes | No |
| 17630391 | METHOD FOR TREATMENT OF HEPATIC CANCER USING REIC/Dkk-3 GENE IN COMBINATION WITH ANTI-TUMOR AGENT | January 2022 | November 2025 | Abandon | 46 | 7 | 0 | No | No |
| 17628118 | CHIMERIC ANTIGEN RECEPTOR T CELLS AND USES THEREOF | January 2022 | June 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17557607 | IMMUNE CELL COMPOSITIONS AND METHODS OF USE | December 2021 | July 2024 | Allow | 30 | 1 | 1 | No | No |
| 17596879 | CULTURE DEVICE | December 2021 | October 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17550219 | BISPECIFIC BINDING PROTEINS AND USES THEREOF | December 2021 | November 2024 | Abandon | 35 | 1 | 0 | No | No |
| 17535898 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER | November 2021 | March 2026 | Abandon | 51 | 2 | 1 | No | Yes |
| 17609972 | Ultraspecific Cell Targeting Using De Novo Designed Co-Localization Dependent Protein Switches | November 2021 | February 2026 | Abandon | 51 | 1 | 1 | No | No |
| 17521335 | IMMUNOREGULATORY AGENT | November 2021 | September 2024 | Allow | 35 | 2 | 1 | Yes | No |
| 17438051 | DETECTION MEANS, COMPOSITIONS AND METHODS FOR MODULATING SYNOVIAL SARCOMA CELLS | September 2021 | January 2026 | Abandon | 52 | 2 | 1 | No | No |
| 17469549 | PD-1 POLYPEPTIDE VARIANTS | September 2021 | October 2025 | Allow | 49 | 5 | 1 | No | No |
| 17464528 | CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR)-EXPRESSING CELL | September 2021 | February 2025 | Allow | 42 | 2 | 0 | No | No |
| 17420739 | BISPECIFIC IN TANDEM RECEPTOR CAR AND METHOD FOR MODULATING THE TUMORAL MICROENVIRONMENT | July 2021 | June 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17364270 | HYBRID IMMUNOGLOBULIN CONTAINING NONPEPTIDYL LINKAGE | June 2021 | August 2025 | Allow | 49 | 2 | 1 | No | No |
| 17292102 | METHODS AND COMPOSITIONS RELATING TO ANTI-CHI3L1 ANTIBODY REAGENTS FOR THE TREATMENT OF FIBROSIS | May 2021 | February 2026 | Abandon | 57 | 3 | 0 | No | No |
| 17290065 | METHODS FOR TREATMENT USING CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR B-CELL MATURATION ANTIGEN | April 2021 | August 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17288406 | TCR AND PEPTIDES | April 2021 | December 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17238059 | ENHANCED ANTIGEN PRESENTING ABILITY OF RNA CAR T CELLS BY CO-INTRODUCTION OF COSTIMULATORY MOLECULES | April 2021 | July 2024 | Allow | 39 | 2 | 1 | No | No |
| 17228843 | METHOD FOR ENHANCING PRODUCTION OF GENETICALLY ENGINEERED AUTOLOGOUS T CELLS | April 2021 | October 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 17284407 | COMPOSITIONS AND METHODS FOR SWITCHABLE CAR T CELLS USING SURFACE-BOUND SORTASE TRANSPEPTIDASE | April 2021 | November 2024 | Allow | 43 | 2 | 0 | Yes | No |
| 17250988 | LET-7 PROMOTES ANTI-TUMOR ACTIVITY OF CD8 T CELLS AND MEMORY FORMATION IN VIVO | April 2021 | October 2025 | Abandon | 54 | 2 | 1 | No | No |
| 17280471 | CD22 CHIMERIC ANTIGEN RECEPTOR (CAR) THERAPIES | March 2021 | November 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17280202 | CD146 AND USES THEREOF AS A BIOMARKER AND AS A THERAPEUTIC TARGET IN THE DIAGNOSIS AND TREATMENT OF FIBROSIS | March 2021 | January 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17202173 | DETERMINANTS OF CANCER RESPONSE TO IMMUNOTHERAPY BY PD-1 BLOCKADE | March 2021 | August 2025 | Allow | 53 | 4 | 1 | No | No |
| 17202018 | THERAPEUTIC CELL COMPOSITIONS AND METHODS OF MANUFACTURING AND USE THEREOF | March 2021 | November 2024 | Allow | 44 | 3 | 1 | Yes | No |
| 17262180 | Individualized Vaccines for Cancer | January 2021 | December 2025 | Allow | 59 | 2 | 1 | No | No |
| 17152031 | ANTI-TUMORAL COMPOSITION | January 2021 | November 2024 | Abandon | 46 | 3 | 0 | No | No |
| 17257469 | CHIMERIC RECEPTORS IN COMBINATION WITH TRANS METABOLISM MOLECULES ENHANCING GLUCOSE IMPORT AND THERAPEUTIC USES THEREOF | December 2020 | January 2025 | Abandon | 48 | 3 | 2 | No | No |
| 16950296 | ANTI-CD79 CHIMERIC ANTIGEN RECEPTORS, CAR-T CELLS, AND USES THEREOF | November 2020 | September 2025 | Allow | 58 | 4 | 1 | Yes | No |
| 17051341 | OCA-B PEPTIDE CONJUGATES AND METHODS OF TREATMENT | October 2020 | July 2024 | Allow | 45 | 2 | 0 | Yes | No |
| 17063505 | TREATMENT OF VIRAL INFECTION | October 2020 | March 2025 | Abandon | 53 | 1 | 0 | No | No |
| 17061998 | ANTI-PD-L1 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | October 2020 | July 2025 | Allow | 57 | 3 | 1 | No | No |
| 17028608 | Payload-Polymer-Protein Conjugates | September 2020 | February 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17025732 | METHODS FOR IMPROVING THE EFFICACY AND EXPANSION OF IMMUNE CELLS | September 2020 | October 2024 | Allow | 49 | 2 | 1 | Yes | Yes |
| 16975725 | Treatment and prevention of pre-eclampsia | August 2020 | October 2024 | Abandon | 50 | 1 | 0 | No | No |
| 16969381 | CHIMERIC ANTIGEN RECEPTOR THERAPY IN COMBINATION WITH IL-15R AND IL15 | August 2020 | October 2024 | Abandon | 50 | 4 | 1 | No | No |
| 16968547 | CYCLIN A1 SPECIFIC T CELL RECEPTORS AND USES THEREOF | August 2020 | November 2025 | Allow | 60 | 2 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner REDDIG, PETER J.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 15.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner REDDIG, PETER J works in Art Unit 1646 and has examined 210 patent applications in our dataset. With an allowance rate of 88.1%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 46 months.
Examiner REDDIG, PETER J's allowance rate of 88.1% places them in the 68% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by REDDIG, PETER J receive 2.95 office actions before reaching final disposition. This places the examiner in the 85% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by REDDIG, PETER J is 46 months. This places the examiner in the 10% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +18.6% benefit to allowance rate for applications examined by REDDIG, PETER J. This interview benefit is in the 61% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 23.6% of applications are subsequently allowed. This success rate is in the 33% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 52.7% of cases where such amendments are filed. This entry rate is in the 79% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 85.0% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 70.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 61.5% are granted (fully or in part). This grant rate is in the 66% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 21.4% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 17.3% of allowed cases (in the 92% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.